# Century Therapeutics, Inc. (IPSC)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $200M  
**Price:** $2.31 (+8.73%)

> Century Therapeutics Inc. is a biotechnology company that focuses on developing innovative cell therapies for cancer treatment. The company's core mission centers around harnessing the potential of induced pluripotent stem cells (iPSCs) to create highly effective, off-the-shelf cellular therapies. By leveraging iPSCs, Century Therapeutics aims to produce uniformly engineered allogeneic cell products designed to target and eliminate cancer cells with precision.

Century Therapeutics operates primarily within the healthcare and biopharmaceutical industry, specifically targeting the oncology sector. It seeks to address unmet medical needs by offering more accessible and potent therapeutic solutions compared to traditional cancer treatments. The company's research and development efforts are focused on using its technology platform to generate natural killer (NK) cells and T cells that possess enhanced tumor-fighting capabilities.

In the financial market, Century Therapeutics plays a vital role in driving innovation in cancer treatment solutions. It represents a segment of biotechnology firms dedicated to advancing cellular immunotherapies, potentially transforming the landscape of cancer care and treatment. The company's work contributes to the growing field of cell therapy, highlighting the importance of biotechnological advances in modern medicine.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $109M | — | -$17M | -$10M | — |
| 2024 | $7M | — | -$138M | -$127M | — |
| 2023 | $2M | — | -$147M | -$137M | — |
| 2022 | $5M | — | -$134M | -$131M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $224M | $65M | $159M | $62M | — |
| 2024 | $353M | $192M | $161M | $58M | — |
| 2023 | $361M | $176M | $185M | $47M | — |
| 2022 | $487M | $184M | $303M | $84M | $10M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$104M | $848,000 | -$105M |
| 2024 | -$110M | $154,000 | -$110M |
| 2023 | -$88M | $14M | -$102M |
| 2022 | $14M | $31M | -$17M |
| 2021 | -$89M | $45M | -$134M |
| 2020 | -$41M | $10M | -$51M |

Source: [CompaniesByCap](https://companiesbycap.com/company/IPSC)